ABSTRACT
BACKGROUND: Recent cryo-electron microscopic imaging studies have shown that in addition to binding to the classical extracellular benzodiazepine binding site of the α1ß3γ2L γ-aminobutyric acid type A (GABAA) receptor, diazepam also binds to etomidate binding sites located in the transmembrane receptor domain. Because such binding is characterized by low modulatory efficacy, the authors hypothesized that diazepam would act in vitro and in vivo as a competitive etomidate antagonist. METHODS: The concentration-dependent actions of diazepam on 20 µM etomidate-activated and 6 µM GABA-activated currents were defined (in the absence and presence of flumazenil) in oocyte-expressed α1ß3γ2L GABAA receptors using voltage clamp electrophysiology. The ability of diazepam to inhibit receptor labeling of purified α1ß3γ2L GABAA receptors by [H]azietomidate was assessed in photoaffinity labeling protection studies. The impact of diazepam (in the absence and presence of flumazenil) on the anesthetic potencies of etomidate and ketamine was compared in a zebrafish model. RESULTS: At nanomolar concentrations, diazepam comparably potentiated etomidate-activated and GABA-activated GABAA receptor peak current amplitudes in a flumazenil-reversible manner. The half-maximal potentiating concentrations were 39 nM (95% CI, 27 to 55 nM) and 26 nM (95% CI, 16 to 41 nM), respectively. However, at micromolar concentrations, diazepam reduced etomidate-activated, but not GABA-activated, GABAA receptor peak current amplitudes in a concentration-dependent manner with a half-maximal inhibitory concentration of 9.6 µM (95% CI, 7.6 to 12 µM). Diazepam (12.5 to 50 µM) also right-shifted the etomidate-concentration response curve for direct activation without reducing the maximal response and inhibited receptor photoaffinity labeling by [H]azietomidate. When administered with flumazenil, 50 µM diazepam shifted the etomidate (but not the ketamine) concentration-response curve for anesthesia rightward, increasing the etomidate EC50 by 18-fold. CONCLUSIONS: At micromolar concentrations and in the presence of flumazenil to inhibit allosteric modulation via the classical benzodiazepine binding site of the GABAA receptor, diazepam acts as an in vitro and in vivo competitive etomidate antagonist.
Subject(s)
Diazepam/pharmacology , Etomidate/antagonists & inhibitors , Hypnotics and Sedatives/pharmacology , Receptors, GABA/drug effects , Animals , Drug Antagonism , Hypnotics and Sedatives/antagonists & inhibitors , Models, Animal , ZebrafishABSTRACT
OBJECTIVE: To evaluate the effect of the peripherally acting α2-adrenoceptor antagonist vatinoxan (MK-467) on the sedative properties of medetomidine (MED) when injected intramuscularly (IM) in the same syringe and on reversal of this sedation with atipamezole in sheep. STUDY DESIGN: Randomized, blinded, crossover experimental trial. ANIMALS: Eight healthy adult female sheep. METHODS: Sheep received MED (30 µg kg-1 IM) alone or combined in the same syringe with vatinoxan (300 µg kg-1 IM, MED+VAT) with a 2 week washout period. Atipamezole (150 µg kg-1 IM) was administered 30 minutes later for reversal. Sedation was assessed using two sedation scores, a visual analog score and a descriptive scale before treatments (T0) and at intervals up to 5 hours thereafter. Pulse rate (PR) was counted at T0 and at 30 (T30) and 90 (T90) minutes. Rectal temperature was measured at T0 and T90 postinjection. Plasma samples were analyzed for drug concentrations at T30 and T90. RESULTS: The first signs of sedation were seen significantly earlier after MED+VAT (4.6 ± 1.7 minutes versus 9.4 ± 2.6 minutes after MED) and the sedation scores were significantly higher after MED+VAT than MED. All animals laid with head down 10.0 ± 3.4 minutes after MED+VAT, whereas three MED animals did not become recumbent before atipamezole was administered. The plasma concentrations of dexmedetomidine were significantly higher at T30 (2.47 ± 0.2 ng mL-1) and significantly lower at T90 (1.23 ± 0.3 ng mL-1) with MED+VAT than with MED (1.19 ± 0.8 and 1.83 ± 0.4 ng mL-1, respectively). While no significant differences were observed between treatments in PR at T30, PR at T90 was significantly higher with MED+VAT than with MED. CONCLUSIONS AND CLINICAL RELEVANCE: When administered IM in the same syringe, vatinoxan hastened and intensified the initial sedative effects of MED and enhanced the sedation reversal by atipamezole.
Subject(s)
Adrenergic alpha-2 Receptor Antagonists/pharmacology , Hypnotics and Sedatives/pharmacology , Imidazoles/pharmacology , Medetomidine/pharmacology , Quinolizines/pharmacology , Animals , Cross-Over Studies , Drug Interactions , Female , Hypnotics and Sedatives/antagonists & inhibitors , Injections, Intramuscular , Medetomidine/antagonists & inhibitors , Quinolizines/antagonists & inhibitors , Sheep , Single-Blind MethodABSTRACT
Eight adult tigers ( Panthera tigris) underwent a complete echocardiographic examination following sedation with medetomidine, midazolam, and induction of general anesthesia using ketamine and isoflurane (phase 1). Atipamezole was used to antagonize medetomidine (phase 2) and a second echocardiographic examination was performed. Physiologic tricuspid and pulmonic regurgitations were common findings in the sample population and one tiger was excluded from final analyses due to the finding of a ventricular septal defect. Measurements and mean arterial pressure were assessed for statistically significant differences between the two examination phases as well as gender and weight. There was a statistically significant difference between interventricular septum thickness at end systole, ejection fraction, and mean arterial pressure between anesthetic phases while fractional shortening and left ventricular internal dimension at end-systole approached, but did not reach, statistical significance between phases. Weight was found to be a statistically significant predictor of stroke volume and left ventricular internal dimension at end-diastole. The echocardiographic measurements obtained during this study can be used as guidelines for future examinations in adult tigers. The effects of medetomidine on these measurements and systolic function should be taken into account when performing echocardiograms and monitoring anesthetic events.
Subject(s)
Anesthesia, General/veterinary , Blood Pressure/drug effects , Echocardiography/veterinary , Hypnotics and Sedatives/antagonists & inhibitors , Imidazoles/administration & dosage , Medetomidine/antagonists & inhibitors , Tigers/physiology , Anesthesia, General/methods , Animals , Female , Hypnotics and Sedatives/administration & dosage , Male , Medetomidine/administration & dosageABSTRACT
BACKGROUND: There is increasing interest in the use of intranasal naloxone to reverse adverse opioid effects during management of procedural pain in children and in adults after overdose. There are limited data on the pharmacokinetics of intranasal naloxone so in this study we aimed to detail the pharmacokinetic profile of the commercially marketed injectable solution of naloxone 0.4 mg/ml when administered as an intranasal spray. METHODS: Twenty healthy volunteers received naloxone as an intranasal spray at a dose of 10 µg/kg. Venous blood sampling was carried out for 90 min after administration to determine the time profile of the plasma concentrations of using tandem mass spectrometry. Pharmacokinetic parameters were calculated using a one-compartment model. RESULTS: Median time to maximum naloxone concentration (Tmax) was 14.5 (95% CI: 9.0-16.5) min, mean maximum naloxone concentration (Cmax) was 1.09 ± 0.56 ng/ml and mean AUC0-90 min was 37.1 ± 15.0 ng*min/ml. Elimination half-life estimated from the median concentration data was 28.2 min. CONCLUSION: Our results show a faster uptake of intranasal naloxone to maximum concentration compared with previous studies although with a marked variation in maximum concentration. The findings are consistent with our clinical experience of the time profile for reversing the effects of sufentanil sedation in children.
Subject(s)
Naloxone/administration & dosage , Naloxone/pharmacokinetics , Narcotic Antagonists/administration & dosage , Narcotic Antagonists/pharmacokinetics , Administration, Intranasal , Adult , Area Under Curve , Chromatography, High Pressure Liquid , Cross-Over Studies , Female , Half-Life , Healthy Volunteers , Humans , Hypnotics and Sedatives/antagonists & inhibitors , Male , Middle Aged , Naloxone/adverse effects , Narcotic Antagonists/adverse effects , Nasal Sprays , Sufentanil/antagonists & inhibitors , Tandem Mass Spectrometry , Young AdultABSTRACT
The practice of midazolam conscious sedation is well established in dentistry. The drug flumazenil is a specific benzodiazepine antagonist and is an essential requirement in settings where midazolam is used. A literature review has been carried out, examining the available information regarding flumazenil's safety, administration, potential complications and the regulatory documentation which governs its use. Flumazenil is a safe drug to use for the reversal of midazolam induced conscious sedation although the evidence surrounding its use is limited.
Subject(s)
Anesthesia, Dental/methods , Conscious Sedation/methods , Flumazenil/therapeutic use , Hypnotics and Sedatives/antagonists & inhibitors , Midazolam/antagonists & inhibitors , HumansABSTRACT
OBJECTIVE: To characterize a propofol-medetomidine-ketamine total intravenous anaesthetic in impala (Aepyceros melampus). STUDY DESIGN: Prospective clinical study. ANIMALS: Ten adult female impala. MATERIALS AND METHODS: Impala were immobilized at 1253 m above sea level with 2.0 mg thiafentanil and 2.2 mg medetomidine via projectile darts. Propofol was given to effect (0.5 mg kg-1 boluses) to allow endotracheal intubation, following which oxygen was supplemented at 2 L minute-1. Anaesthesia was maintained with a constant-rate infusion of medetomidine and ketamine at 5 µg kg-1 hour-1 and 1.5 mg kg-1 hour-1, respectively, and propofol to effect (initially 0.2 mg kg-1 minute-1) for 120 minutes. The propofol infusion was titrated according to reaction to nociceptive stimuli every 15 minutes. Cardiopulmonary parameters were monitored continuously and arterial blood gas samples were analysed intermittently. After 120 minutes' maintenance, the thiafentanil and medetomidine were antagonized using naltrexone (10:1 thiafentanil) and atipamezole (5:1 medetomidine), respectively. RESULTS: All impala were successfully immobilized. The median dose [interquartile range (IQR)] of propofol required for intubation was 2.7 (1.9-3.3) mg kg-1. The propofol-medetomidine-ketamine combination abolished voluntary movement and ensured anaesthesia for the 120 minute period. Propofol titration showed a generally downward trend. Median (IQR) heart rate [57 (53-61) beats minute-1], respiratory rate [10 (9-12) breaths minute-1] and mean arterial blood pressure [101 (98-106) mmHg] were well maintained. Arterial blood gas analysis indicated hypoxaemia, hyper- capnia and acidaemia. Butorphanol (0.12 mg kg-1) was an essential rescue drug to counteract thiafentanil-induced respiratory depression. All impala regurgitated frequently during the maintenance period. Recovery was calm and rapid in all animals. Median (IQR) time to standing from antagonist administration was 4.4 (3.2-5.6) minutes. CONCLUSIONS AND CLINICAL RELEVANCE: A propofol-medetomidine-ketamine combination could provide adequate anaesthesia for invasive procedures in impala. The propofol infusion should begin at 0.2 mg kg-1 minute-1 and be titrated to clinical effect. Oxygen supplementation and airway protection with a cuffed endotracheal tube are essential.
Subject(s)
Anesthesia, Intravenous/veterinary , Anesthetics, Combined/administration & dosage , Antelopes , Fentanyl/analogs & derivatives , Hypnotics and Sedatives/administration & dosage , Ketamine/administration & dosage , Medetomidine/administration & dosage , Propofol/administration & dosage , Adrenergic alpha-2 Receptor Antagonists/administration & dosage , Anesthesia, Intravenous/methods , Animals , Female , Fentanyl/administration & dosage , Fentanyl/antagonists & inhibitors , Heart Rate/drug effects , Hypnotics and Sedatives/antagonists & inhibitors , Imidazoles/administration & dosage , Medetomidine/antagonists & inhibitors , Naltrexone/administration & dosage , Narcotic Antagonists/administration & dosage , Prospective Studies , Respiratory Rate/drug effectsABSTRACT
BACKGROUND: Ethanol is widely known for its depressant effects; however, the underlying neurobiological mechanisms are not clear. Calcium-activated anion channels (CAACs) contribute to extracellular chloride levels and thus may be involved in regulating inhibitory mechanisms within the central nervous system. Therefore, we hypothesized that CAACs influence ethanol behavioral sensitivity by altering CAAC expression. METHODS: We assessed the role of CAACs in ethanol-induced loss of righting reflex (LORR) and locomotor activity using intracerebroventricular infusions of several nonselective CAAC blockers. CAAC expression was determined after ethanol exposure. RESULTS: Ethanol-induced LORR (4.0 g/kg, intraperitoneally [i.p.]) was significantly attenuated by all 4 CAAC blockers. Blocking CAACs did not impact ethanol's low-dose (1.5 g/kg, i.p.) locomotor-impairing effects. Biochemical analysis of CAAC protein expression revealed that cortical Bestrophin1 (Best1) and Tweety1 levels were reduced as early as 30 minutes following a single ethanol injection (3.5 g/kg, intraperitoneally [i.p.]) and remained decreased 24 hours later in P2 fractions. Cortical Best1 levels were also reduced following 1.5 g/kg. However, CAAC expression was unaltered in the striatum following a single ethanol exposure. Ethanol did not affect Tweety2 levels in either brain region. CONCLUSIONS: These results suggest that CAACs are a major target of ethanol in vivo, and the regulation of these channels contributes to select behavioral actions of ethanol.
Subject(s)
Calcium Channel Blockers/pharmacology , Calcium Channels/drug effects , Ethanol/pharmacology , Hypnotics and Sedatives/antagonists & inhibitors , 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid/pharmacology , Animals , Blotting, Western , Brain Chemistry/drug effects , Calcium Channels/analysis , Ethanol/antagonists & inhibitors , Flufenamic Acid/pharmacology , Hypnotics and Sedatives/pharmacology , Male , Motor Activity/drug effects , Niflumic Acid/pharmacology , Nitrobenzoates/pharmacology , Rats , Rats, Sprague-Dawley , Reflex, Righting/drug effectsABSTRACT
BACKGROUND: Moderate sedation has been standard for noninvasive gastrointestinal procedures for decades yet there are limited data on reversal agent use and outcomes associated with need for reversal of sedation. AIM: To determine prevalence and clinical significance of reversal agent use during endoscopies and colonoscopies. METHODS: Individuals with adverse events requiring naloxone and/or flumazenil during endoscopy or colonoscopy from 2008 to 2013 were identified. A control group was obtained by random selection of patients matched by procedure type and date. Prevalence of reversal agent use and statistical comparison of patient demographics and risk factors against controls were determined. RESULTS: Prevalence of reversal agent use was 0.03% [95% confidence interval (CI), 0.02-0.04]. Events triggering reversal use were oxygen desaturation (64.4%), respiration changes (24.4%), hypotension (8.9%), and bradycardia (6.7%). Two patients required escalation of care and the majority of patients were stabilized and discharged home. Compared with the control group, the reversal group was older (61±1.8 vs. 55±1.6, P=0.01), mostly female (82% vs. 50%, P<0.01), and had lower body mass index (24±0.8 vs. 27±0.7, P=0.03) but received similar dosages of sedation. When adjusted for age, race, sex, and body mass index, the odds of reversal agent patients having a higher ASA score than controls was 4.7 (95% CI, 1.7-13.1), and the odds of having a higher Mallampati score than controls was 5.0 (95% CI, 2.1-11.7) with P<0.01. CONCLUSIONS: Prevalence of reversal agent use during moderate sedation is low and outcomes are generally good. Several clinically relevant risk factors for reversal agent use were found suggesting that certain groups may benefit from closer monitoring.
Subject(s)
Antidotes/administration & dosage , Colonoscopy , Conscious Sedation/adverse effects , Health Status , Hypnotics and Sedatives/antagonists & inhibitors , Narcotic Antagonists/administration & dosage , Age Factors , Anti-Arrhythmia Agents/administration & dosage , Atropine/administration & dosage , Body Mass Index , Bradycardia/chemically induced , Bradycardia/drug therapy , Case-Control Studies , Colonoscopy/adverse effects , Female , Fentanyl/adverse effects , Fentanyl/antagonists & inhibitors , Flumazenil/administration & dosage , Humans , Hypnotics and Sedatives/adverse effects , Hypotension/chemically induced , Hypotension/drug therapy , Hypoxia/chemically induced , Hypoxia/drug therapy , Male , Midazolam/adverse effects , Midazolam/antagonists & inhibitors , Middle Aged , Naloxone/administration & dosage , Sex Factors , Treatment OutcomeABSTRACT
We investigated the effects of acute diazepam (DZP) administration on thiobarbituric acid-reactive substance (TBARS) levels, protein carbonyl content, and on the activities of the antioxidant enzymes catalase, glutathione peroxidase, and superoxide dismutase in the brain of rats. Additionally, we investigated the antioxidant role of chronic pretreatment with simvastatin on the effects provoked by DZP. Simvastatin was administered (1 or 10 mg/kg by oral gavage) for 30 days. On the 30th day of treatment, groups were randomized and DZP was administered (0.5 or 1.0 mg/kg by intraperitoneal injection). Control groups received saline. Results showed that DZP enhanced TBARS levels and protein carbonyl content and altered enzymatic activity in the brain of rats. Simvastatin prevented most of the alterations caused by DZP on the oxidative stress parameters. Data indicate that DZP administration causes an oxidative imbalance in the brain areas studied; however, in the presence of simvastatin, some of these alterations in oxidative stress were prevented.
Subject(s)
Anticholesteremic Agents/pharmacology , Diazepam/adverse effects , Hypnotics and Sedatives/adverse effects , Oxidative Stress/drug effects , Simvastatin/pharmacology , Administration, Oral , Animals , Brain/drug effects , Brain/metabolism , Catalase/metabolism , Diazepam/antagonists & inhibitors , Drug Administration Schedule , Glutathione Peroxidase/metabolism , Hypnotics and Sedatives/antagonists & inhibitors , Injections, Intraperitoneal , Lipid Peroxidation/drug effects , Oxidation-Reduction , Protein Carbonylation/drug effects , Rats , Rats, Wistar , Superoxide Dismutase/metabolism , Thiobarbituric Acid Reactive Substances/metabolismABSTRACT
We investigated the influence of the peripherally acting α2 -adrenoceptor antagonist MK-467 on the sedative and antinociceptive actions and plasma drug concentrations of medetomidine, an α2 -adrenoceptor agonist that is used in veterinary medicine as a sedative and analgesic agent. Eight healthy beagle dogs received intravenous medetomidine (10 µg/kg) or medetomidine with MK-467 (250 µg/kg) in a randomized crossover design. A standardized nociceptive pressure stimulus was applied to a nail bed of a hindlimb. Times for withdrawal of the limb and for head lift were measured, and sedation was scored. EEG data were collected prior to and after stimulation. Plasma drug concentrations were measured. Co-administration of MK-467 significantly attenuated medetomidine analgesia, as assessed with limb withdrawal, and also shortened the duration of sedation. The apparent plasma clearance of both enantiomers of medetomidine, dexmedetomidine and levomedetomidine, was more than doubled in the presence of MK-467. Antagonism by MK-467 of medetomidine-evoked vasoconstriction is seen as the mechanism behind this pharmacokinetic drug interaction. Thus, MK-467 attenuated the antinociceptive and sedative effects of medetomidine. This can probably be explained by increased clearance and decreased concentrations of dexmedetomidine in plasma after co-administration of MK-467 with racemic medetomidine.
Subject(s)
Analgesics/pharmacokinetics , Hypnotics and Sedatives/antagonists & inhibitors , Medetomidine/antagonists & inhibitors , Quinolizines/pharmacology , Analgesics/pharmacology , Analgesics/therapeutic use , Animals , Dogs , Drug Interactions , Electroencephalography/drug effects , Electroencephalography/veterinary , Female , Hypnotics and Sedatives/pharmacokinetics , Hypnotics and Sedatives/pharmacology , Hypnotics and Sedatives/therapeutic use , Male , Medetomidine/pharmacokinetics , Medetomidine/pharmacology , Medetomidine/therapeutic use , Pain Measurement/veterinaryABSTRACT
Hispidulin is well-known natural bioactive flavone on behalf of its pharmacological aspects. This review contains data on isolation, synthetic methodology, pharmacokinetics and bioactivities of hispidulin. The article provides a critical assessment of present knowledge about hispidulin with some clear conclusions, perspectives and directions for future research in potential applications.
Subject(s)
Flavones/pharmacology , Animals , Anti-Inflammatory Agents, Non-Steroidal/pharmacokinetics , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Antineoplastic Agents, Phytogenic/pharmacokinetics , Antineoplastic Agents, Phytogenic/pharmacology , Antioxidants/pharmacokinetics , Antioxidants/pharmacology , Flavones/chemical synthesis , Flavones/pharmacokinetics , Humans , Hypnotics and Sedatives/antagonists & inhibitors , Mitochondria , Platelet Aggregation Inhibitors/pharmacokinetics , Platelet Aggregation Inhibitors/pharmacology , Protective Agents/pharmacokinetics , Protective Agents/pharmacologyABSTRACT
INTRODUCTION: Analyzing hospital naloxone use may assist in identification of areas for quality and safety improvement. Our primary objective is to quantitate the incidence of hospital naloxone use and to assess certain patient populations at risk. METHODS: During the years 2008 to 2011, each clinical scenario where naloxone was administered on an in-patient care ward was reviewed. The events were assessed to separate situations where naloxone rescue was effective in reversing opioid-induced intoxication vs. others. Further analysis was conducted to stratify patient populations at greatest risk. RESULTS: Naloxone was administered for well-defined opioid-induced respiratory depression and oversedation 61% of the time, the remainder used for patient deterioration of other etiology. Surgical populations are at risk with an incidence of 3.8/1,000 hospitalized patients, and this is the greatest within 24 hours of surgery. General surgical patients represent the highest surgical patient risk at 5.5/1,000. Medical patients represent lower risk at 2.0/1,000. Patients with patient-controlled analgesia and epidural opioid infusion are high risk at 12.1 and 13.1/1,000 patients, respectively. Many quality and safety interventions were gradually implemented in response to this data and are summarized. These include nursing and provider education, electronic medical record modification, and more stringent patient monitoring practices. CONCLUSION: Examination of naloxone use can assist in the identification and stratification of patients at risk for opioid-induced respiratory depression and oversedation and can serve as a driver for improvements in hospital patient safety. This information can also guide other institutions interested in similar improvements.
Subject(s)
Naloxone/therapeutic use , Narcotic Antagonists/therapeutic use , Adult , Aged , Analgesia, Epidural , Analgesia, Patient-Controlled , Analgesics, Opioid/antagonists & inhibitors , Analgesics, Opioid/poisoning , Databases, Factual , Female , Humans , Hypnotics and Sedatives/adverse effects , Hypnotics and Sedatives/antagonists & inhibitors , Incidence , Male , Middle Aged , Naloxone/adverse effects , Narcotic Antagonists/adverse effects , Patient Education as Topic , Patient Safety , Respiratory Insufficiency/chemically induced , Respiratory Insufficiency/drug therapy , Risk Assessment , Tertiary Care CentersABSTRACT
OBJECTIVE: To assess the sedative and immobilization effect of intranasal administration (INS) of midazolam (MID) without or with INS dexmedetomidine (DXM), and some physiological changes induced by the drugs. The ability of INS atipamezole to reverse the DXM component was also assessed. STUDY DESIGN: Prospective 'blinded' experimental study. ANIMALS: In total, 15 pigeons. METHODS: Pigeons were sedated by INS MID alone at a dose of 5 mg kg(-1) (group MID, n = 6) or in combination with INS DXM at a dose 80 µg kg(-1) (group MID-DXM, n = 6). Measurements were made of heart rate (HR), respiratory rate (fR ) and cloacal temperature (CT). The degree of sedation was assessed at 15 minutes prior to, immediately after, and at intervals until 100 minutes after drug administrations. Following MID-DXM, INS atipamezole (250 µg kg(-1) ) was administered and the same indices measured 5 and 10 minutes later. RESULTS: MID had no effect on HR and fR , and although CT decreased, it remained within physiological range. MID-DXM caused significant falls in HR, fR and CT that persisted until the end of sedation. Atipamezole antagonized sedation and cardiorespiratory side effects of MID-DXM within 10 minutes of application. In addition, for MID compared to MID-DXM, the lowest sedation scores [10 (7-14) and 10.5 (5-14) versus 2 (1-4) and 2 (1-5)] were achieved in the 10th and 20th minute versus the 20th and 30th minute of the sedation, respectively. CONCLUSIONS AND CLINICAL RELEVANCE: MID alone, given INS had minimal side effects on vital functions but caused inadequate immobilization of pigeons for restraint in dorsal recumbency. MID-DXM caused an effective degree of immobilization from 20 to 30 minutes after administration, at which time birds tolerated postural changes without resistance. Atipamezole antagonized both side effects and sedation, but complete recovery had not occurred within 10 minutes after its application.
Subject(s)
Anesthetics, Combined/administration & dosage , Columbidae , Deep Sedation/veterinary , Dexmedetomidine , Hypnotics and Sedatives/administration & dosage , Imidazoles/therapeutic use , Immobilization/veterinary , Midazolam , Administration, Intranasal/veterinary , Animals , Body Temperature/drug effects , Deep Sedation/methods , Dexmedetomidine/administration & dosage , Dexmedetomidine/antagonists & inhibitors , Heart Rate/drug effects , Hypnotics and Sedatives/antagonists & inhibitors , Immobilization/methods , Midazolam/administration & dosage , Midazolam/antagonists & inhibitorsABSTRACT
BACKGROUND: Endoscopy under midazolam sedation requires a 2-h recovery facility. AIM: To study the potential of shortening patients' stay without jeopardizing patients' safety by the use of the benzodiazepine-antagonist flumazenil in the everyday practice and to investigate the feasibility of a study comparing midazolam with recovery with midazolam-flumazenil and immediate discharge. METHODS: Consecutive ambulatory patients referred for endoscopy under midazolam sedation with ASA I or II, escorted by a person, were eligible. Flumazenil was given on arrival in the recovery room. Patients were discharged when adequate Aldrete scores and physical mobility were present. The next day, they were contacted by telephone. RESULTS: A total of 1,506 patients participated. They received 5 mg midazolam, while 887 patients also received 50 mcg fentanyl. The median dose of flumazenil was 0.2 mg. Oxygen desaturation (sO2 <92%) occurred in 15% during the procedure without an effect on recovery and discharge times. Patients left the department 65 min after the last midazolam administration. The majority (82.7%) were fully alert during their journey home. At home, 2.7% went to bed, 45.2% took a nap, and 40% undertook activities. Almost every patient (98.8%) liked the shortened recovery time. Three patients had an incident (fainting, fall, and near-fall) without consequences. Based on this low incidence, a non-inferiority comparison of midazolam-flumazenil with midazolam-recovery would require a total of 32,650 patients. CONCLUSIONS: Administration of flumazenil resulted in a safe shortening of the recovery period and offers the possibility for substantial savings in time, space, and nurse resources. A non-inferiority comparison will not be practicable.
Subject(s)
Antidotes/administration & dosage , Conscious Sedation/methods , Endoscopy, Digestive System , Flumazenil/administration & dosage , Hypnotics and Sedatives/antagonists & inhibitors , Midazolam/antagonists & inhibitors , Adolescent , Adult , Aged , Aged, 80 and over , Conscious Sedation/adverse effects , Endoscopy, Digestive System/adverse effects , Feasibility Studies , Female , Humans , Hypnotics and Sedatives/administration & dosage , Male , Midazolam/administration & dosage , Middle Aged , Patient Satisfaction , Recovery of Function , Young AdultABSTRACT
Chloral hydrate is the most commonly used sedative for paediatric diagnostic procedures in China with a success rate of around 80%. Intranasal dexmedetomidine is used for rescue sedation in our centre. This prospective investigation evaluated 213 children aged one month to 10 years who were not adequately sedated following administration of chloral hydrate. Children were randomly assigned to receive rescue intranasal dexmedetomidine at 1 µg.kg(-1) (group 1), 1.5 µg.kg(-1) (group 2) or 2 µg.kg(-1) (group 3). The sedation level was assessed every 10 min using a modified observer's assessment of alertness/sedation scale. Successful rescue sedation in groups 1, 2 and 3 were 56 (83.6%), 66 (89.2%) and 51 (96.2%), respectively. Increasing the rescue dose was associated with an increased success rate with an odds ratio of 4.12 (95% CI 1.13-14.98), p = 0.032. We conclude that intranasal dexmedetomidine is effective for sedation in children who do not respond to chloral hydrate.
Subject(s)
Chloral Hydrate/adverse effects , Chloral Hydrate/antagonists & inhibitors , Conscious Sedation , Dexamethasone/pharmacology , Hypnotics and Sedatives/adverse effects , Hypnotics and Sedatives/antagonists & inhibitors , Administration, Intranasal , Child, Preschool , Dexamethasone/administration & dosage , Female , Humans , Infant , Male , Odds Ratio , Prospective Studies , Treatment FailureABSTRACT
High doses of phenylephrine and diazepam (1 and 10 mg/kg, respectively) suppressed the development of generalized tonic-clonic pentylenetetrazole-induced convulsions in 86-100% rats, but did not prevent local clonic pentylenetetrazole-induced convulsions. Diazepam in the specified dose produced strong sedation, while phenylephrine had no sedative effect in the open-field test. Combined intragastric administration of phenylephrine in a medium and individually ineffective dose (0.3 mg/kg) and diazepam in a high dose (10 mg/kg) potentiated the anticonvulsant effect of diazepam: it prevented not only tonic-clonic, but also clonic pentylenetetrazole-induced convulsions in 100% rats and 2.6-fold increased anticonvulsant activity of diazepam. The specified combination of diazepam and phenylephrine had no sedative effect. The mechanism of potentiation of the anticonvulsive effect and elimination of the sedative side effect is based on stimulation of gastric mucosa afferents by phenylephrine.
Subject(s)
Anticonvulsants/pharmacology , Diazepam/antagonists & inhibitors , Epilepsy, Tonic-Clonic/prevention & control , Hypnotics and Sedatives/antagonists & inhibitors , Phenylephrine/pharmacology , Animals , Anticonvulsants/administration & dosage , Diazepam/administration & dosage , Diazepam/pharmacology , Dose-Response Relationship, Drug , Drug Combinations , Drug Evaluation, Preclinical , Drug Synergism , Gastric Mucosa/drug effects , Hypnotics and Sedatives/administration & dosage , Hypnotics and Sedatives/pharmacology , Male , Phenylephrine/administration & dosage , Rats , Rats, Wistar , Statistics, NonparametricABSTRACT
OBJECTIVE: To study an expediency and efficacy of application of different reverses drugs (naloxone, flumazenil, neostigmine, galantamine, sugammadex) either their separate or combined using. METHODS: We studied 119 patients underwent endoluminal endoscopic procedures and surgeries on trachea-bronchial tree and intestines under sedation or general anaesthesia. RESULTS: The article deals with conceptual approaches to the reversal of residual effects of opioids, benzodiazepine sedation and neuromuscular block (the so-called agonist-antagonist technique). CONCLUSIONS: A reversion of neuromuscular block without using of antagonists' combination does not provide complete recovery of psychomotor and cognitive functions for rapid socialization of patients after anaesthesia.
Subject(s)
Anesthesia, General/methods , Anesthetics, General/administration & dosage , Cholinergic Antagonists/administration & dosage , Deep Sedation/methods , Hypnotics and Sedatives/antagonists & inhibitors , Narcotic Antagonists/administration & dosage , Neuromuscular Blocking Agents/antagonists & inhibitors , Adolescent , Adult , Aged , Anesthesia Recovery Period , Anesthetics, General/adverse effects , Anesthetics, General/pharmacokinetics , Blood Pressure/drug effects , Cholinergic Antagonists/adverse effects , Drug Therapy, Combination , Female , Heart Rate/drug effects , Humans , Hypnotics and Sedatives/administration & dosage , Hypnotics and Sedatives/adverse effects , Hypnotics and Sedatives/pharmacokinetics , Male , Middle Aged , Narcotic Antagonists/adverse effects , Neuromuscular Blocking Agents/administration & dosage , Neuromuscular Blocking Agents/adverse effects , Neuromuscular Blocking Agents/pharmacokinetics , Young AdultABSTRACT
BACKGROUND: Flumazenil is generally administered to antagonise the sedative effect of midazolam. However, although flumazenil completely antagonises the sedative effect of midazolam, a few effects remain unantagonised. Hence, it is unclear whether flumazenil restores the attenuation of the arterial-cardiac baroreflex (i.e. arterial-heart rate reflex) induced by midazolam. We investigated the antagonistic effect of flumazenil administered after midazolam on cardiac baroreflex, to reveal whether complete recovery from midazolam-induced sedation by flumazenil administration is accompanied by restoration of midazolam's attenuating effects on the cardiac baroreflex. METHOD: Twelve healthy male subjects received midazolam followed by flumazenil until complete recovery from midazolam sedation. Before and during midazolam sedation, and after flumazenil administration, cardiac baroreflex function was assessed by sequence analysis and transfer function analysis between spontaneous oscillations in systolic arterial pressure and R-R interval. RESULTS: During midazolam sedation, defined by an Observer's Assessment of Alertness/Sedation scale score of 3, BIS value decreased significantly. Simultaneously, the baroreflex indices of the two analyses decreased significantly compared with baseline, suggesting attenuated cardiac baroreflex function. With complete recovery from midazolam sedation by flumazenil, indicated by an Observer's Assessment of Alertness/Sedation scale score of 5, BIS values returned to the baseline level. Simultaneously, cardiac baroreflex indices also returned to baseline levels. CONCLUSION: The present results suggest that complete recovery from midazolam sedation by flumazenil is accompanied by restoration of the attenuated cardiac baroreflex function induced by midazolam.
Subject(s)
Baroreflex/drug effects , Flumazenil/pharmacology , Hypnotics and Sedatives/antagonists & inhibitors , Midazolam/antagonists & inhibitors , Adult , Electrocardiography/drug effects , Electroencephalography/drug effects , Humans , Male , Systole/drug effectsABSTRACT
BACKGROUND: 5-HT(1A)-R-agonist repinotan was shown to counteract a morphine-induced ventilatory depression but had pronociceptive effects at small doses (0.2 µg/kg). It remained to be clarified (1) whether a moderate dose of repinotan, sufficient to stimulate spontaneous breathing, impairs antinociception if plasma concentration decreases over time, and if (2) moderate doses prevent ventilatory depression if given before the opioid. METHODS: A dose-response curve of the repinotan effects on spontaneous minute ventilation during continuous remifentanil infusion in anesthetized rats was established to identify moderate doses: (1) tail-flick reflex latencies to assess nociception were recorded until 60 min after cessation of a continuous remifentanil infusion with or without a concomitant moderate repinotan dose (10 µg/kg), and (2) remifentanil boluses (2.5 µg/kg) were given after repinotan (10 and 20 µg/kg). RESULTS: (1) Remifentanil-induced antinociception lasted only 5 min after infusion was stopped (tail-flick reflex latencies; median [interquartile range], 97 [54-100]% of maximum possible effect; P = 0.034), but was extended by repinotan (10 µg/kg) to 30 min (tail-flick reflex latencies, 100 [75-100]% of maximum possible effect; P = 0.031). Repinotan (10 µg/kg) alone did not have any significant antinociceptive effect. (2) The ventilatory depression by remifentanil boluses (2.5 µg/kg; minute ventilation, -65 [-81 to -56]%; P = 0.031, n = 5) was blunted by repinotan (20 µg/kg; minute ventilation, -24 [-53 to 13]%; P = 0.313, compared with the pretreatment level). CONCLUSIONS: Repinotan prevented remifentanil-induced ventilatory depression in spontaneously breathing, anesthetized rats. Although repinotan did not depress nociception itself, it prolonged the profound antinociception after discontinuation of remifentanil infusion.
Subject(s)
Analgesics, Opioid/pharmacology , Anesthetics, Intravenous/antagonists & inhibitors , Benzopyrans/pharmacology , Hypnotics and Sedatives/antagonists & inhibitors , Piperidines/antagonists & inhibitors , Receptor, Serotonin, 5-HT1A/drug effects , Respiratory Insufficiency/prevention & control , Serotonin Receptor Agonists/pharmacology , Thiazoles/pharmacology , Anesthetics, Intravenous/pharmacology , Anesthetics, Intravenous/toxicity , Animals , Blood Pressure/drug effects , Dose-Response Relationship, Drug , Heart Rate/drug effects , Hemodynamics/drug effects , Hypnotics and Sedatives/pharmacology , Hypnotics and Sedatives/toxicity , Male , Pain Measurement/drug effects , Piperidines/pharmacology , Piperidines/toxicity , Rats , Rats, Sprague-Dawley , Remifentanil , Respiratory Insufficiency/chemically induced , Respiratory Mechanics/drug effectsABSTRACT
Opioid analgesics are the mainstay of treatment of moderate and severe pain. Remifentanil is an ultrashort acting opioid analgesic used in emergency department (ED)procedural sedation, whereas buprenorphine/naloxone (Suboxone) is an opioid agonist-antagonist combination used in the treatment of addiction-prone individuals. We report here a case of buprenorphine/naloxone inhibition of remifentanil analgesia in a patient undergoing ED procedural sedation.